Pathology Workflow: A Breakdown From Sample to Diagnosis

A tissue sample’s journey from operating room to pathology report involves a tightly choreographed sequence of chemical, mechanical, and interpretive steps, each of which can influence the final diagnosis. What most patients experience as a vague waiting period after a biopsy or surgery actually spans specimen collection, chemical fixation, tissue processing, thin-section cutting, staining, microscopic examination, and increasingly, molecular testing and digital analysis. Understanding how these steps connect helps explain why results take days rather than minutes, and why errors at any single stage can cascade downstream.

Specimen Collection and Fixation

The workflow begins the moment a surgeon or proceduralist removes tissue from the body. From that point, a biological clock starts ticking. Living cells deprived of blood supply begin to degrade almost immediately through a process called autolysis, where the tissue’s own enzymes start breaking it down. The standard countermeasure is fixation, which chemically preserves the tissue’s structure. In the vast majority of pathology labs, the fixative of choice is 10% neutral buffered formalin, a diluted formaldehyde solution that cross-links proteins and halts degradation.

Timing matters more than most people realize. Fixation should ideally begin within 30 minutes of surgical removal, and the tissue should soak for a controlled period, generally not exceeding 24 to 48 hours.¹ Too little time in formalin and the tissue won’t be adequately preserved; too much time and the fixative can chemically alter the very molecules pathologists need to detect later. The pH and concentration of the formalin solution also influence outcomes. Comprehensive testing has shown that low pH and short fixation times can inflate certain staining results, while prolonged fixation impairs the ability to amplify DNA and RNA from the tissue. Based on these trade-offs, labs generally aim for 10% neutral buffered formalin with fixation times kept under one week to balance reliable staining with successful molecular testing.²

Tissue Processing and Embedding

Fixed tissue is still far too soft and wet to cut into the ultra-thin slices a microscope requires. The next stage, tissue processing, replaces the water in the specimen with paraffin wax through three sequential steps: dehydration (running the tissue through increasing concentrations of alcohol), clearing (using a solvent like xylene to remove the alcohol), and infiltration (saturating the tissue with molten paraffin).³ Most labs accomplish this with automated tissue processors that cycle the specimen through a series of chemical baths overnight.

Once processing is complete, a histotechnologist orients the tissue in a small mold and pours in molten paraffin wax. When the wax cools and hardens, the result is a paraffin block, a firm, cuttable unit that preserves the architecture of the original tissue. Good orientation at this step is quietly critical: if a skin biopsy is embedded on its side rather than perpendicular to the surface, the pathologist might not see the layers they need to evaluate the depth of a lesion.

Microtomy and Slide Preparation

The paraffin block is mounted on a microtome, a precision instrument with an extremely sharp blade that shaves sections typically four to five micrometers thick, roughly one-twentieth the width of a human hair. These ribbons of tissue float on a warm water bath to flatten out wrinkles, then are picked up onto glass slides. Skill matters here. A dull blade, improper angle, or wrong water temperature can introduce folds, tears, or chattering artifacts that obscure the tissue’s real structure. Even tiny air bubbles trapped beneath the section can mimic pathological features under the microscope.

Preanalytical variables at every stage up to this point, from the time the tissue spent without fixation, to labeling errors, to how thickly the tissue was sliced at the grossing bench, can compromise the final slide’s quality and ultimately the diagnosis.⁴ Labs invest heavily in quality control at each of these handoff points precisely because mistakes here are invisible by the time the pathologist sits down at the microscope.

Staining the Tissue

An unstained tissue section is nearly transparent under a standard light microscope, so staining is essential. The workhorse of pathology is the hematoxylin and eosin (H&E) stain, used on virtually every surgical pathology case. Hematoxylin produces a deep blue-purple color and binds to nucleic acids, highlighting cell nuclei. Eosin is pink and stains proteins nonspecifically, coloring the cytoplasm and surrounding connective tissue in varying shades of pink.⁵ The contrast between blue nuclei and pink cytoplasm gives pathologists most of the architectural and cellular detail they need for a preliminary assessment.

When H&E alone cannot answer the diagnostic question, special stains come into play. These use specific chemical interactions to highlight particular tissue components. Periodic Acid–Schiff (PAS) lights up glycogen and fungal organisms. Alcian Blue marks acidic mucins. Congo Red reveals amyloid deposits. Silver-based stains pick out melanin, reticulin fibers, and certain microorganisms.⁶ In infectious disease workups, special stains significantly improve the ability to identify the causative organism compared to H&E alone.⁷

Immunohistochemistry

Beyond traditional chemical stains, immunohistochemistry (IHC) uses antibodies to detect specific proteins in tissue sections. An antibody is designed to bind to a particular target protein, and a color-producing detection system makes that binding visible under the microscope. This is how pathologists determine, for instance, whether a breast cancer overexpresses HER2 (a protein that guides treatment decisions) or whether a tumor of uncertain origin is actually a lymphoma, a carcinoma, or a sarcoma.

IHC’s diagnostic power depends heavily on proper fixation. The formalin that preserves the tissue also chemically masks some of the protein targets the antibodies need to find. A technique called antigen retrieval, typically using heat or enzymes, reverses some of this masking and restores the antibody’s ability to bind. Over the past two decades, antigen retrieval has become foundational to nearly all IHC-based diagnosis and research.⁸ Because overfixation can permanently damage these protein targets, the fixation step discussed earlier has a direct, practical impact on IHC results downstream.

Frozen Sections and Intraoperative Consultation

Not every case follows the standard multi-day timeline. During surgery, a surgeon sometimes needs an answer in minutes, not days. Is this tissue at the edge of the resection free of cancer? Is this mass a malignancy that requires a wider excision? For these urgent questions, pathologists perform frozen sections. Instead of formalin fixation and paraffin embedding, the fresh tissue is rapidly frozen (usually with a cryostat), cut, stained, and examined on the spot. A preliminary diagnosis is phoned to the operating room within about 15 to 20 minutes.

Frozen sections trade some quality for speed. The ice crystals that form during rapid freezing create artifacts not present in standard paraffin-processed tissue, and the sections are thicker and harder to interpret. Still, the technique is remarkably accurate. Studies at tertiary care centers report overall accuracy rates in the range of 94 to 98%, with specificity consistently above 97%.^{9 10} In specialized settings like hepato-pancreato-biliary surgery, accuracy has been reported as high as about 98%, with most discordances traced to technical issues rather than misinterpretation.¹¹ The permanent sections processed through the standard workflow remain the gold standard, and every frozen section diagnosis is later confirmed or revised against them.

Cytopathology and Cell Blocks

Not all pathology specimens are solid tissue. Fluid samples, such as pleural effusions, urine, or material aspirated through a fine needle, go through a somewhat different pipeline. Cytopathology examines individual cells or small cell clusters rather than intact tissue architecture. A smear of cells on a slide can be stained and examined directly, but for many clinical purposes, converting the fluid into a cell block is preferable. A cell block is essentially a paraffin-embedded version of a cytology specimen, allowing pathologists to cut thin sections and apply the same IHC and special stains used on surgical tissue.¹²

The catch is that cell block preparation is more variable than standard tissue processing. There are many different protocols in use, and no single method has emerged as a universal standard.¹³ This variability can affect cell yield, staining quality, and the amount of material available for molecular testing. Labs often develop their own preferred technique based on case volume and the types of specimens they commonly receive.

Molecular Diagnostics

Modern pathology increasingly extends beyond what the microscope can see. Molecular diagnostics extract DNA, RNA, or proteins from tissue specimens and analyze them for mutations, gene fusions, or other alterations that guide treatment. In oncology, this is now routine: the same paraffin block used for H&E and IHC often has additional sections sent for next-generation sequencing (NGS).

Formalin-fixed, paraffin-embedded (FFPE) tissue is far from ideal for molecular work. The fixation process chemically modifies DNA, introducing cross-links and other damage that can lead to incorrect sequences or artifacts in downstream analysis.¹⁴ Labs use specialized DNA extraction kits and repair enzymes to mitigate this damage, and the choice of extraction method can influence the results. Comparative evaluations have found that genotype concordance across different extraction methods can reach about 99% for targeted panels, though whole-exome sequencing shows slightly more variability at around 96%.¹⁵ RNA-based testing, important for detecting gene fusions in cancers like lung adenocarcinoma, is even more sensitive to extraction method. Some kits detect fusions that others miss entirely.¹⁶

Digital Pathology and AI

The traditional endpoint of the pathology workflow is a pathologist looking at glass slides through a microscope. Digital pathology is changing that. Whole-slide imaging (WSI) scanners create high-resolution digital files of entire slides, which pathologists can review on a computer monitor. This enables remote consultation, archiving, and computational analysis. Validation guidelines from the College of American Pathologists recommend that labs compare diagnoses made on digital images to those made on glass slides across at least 60 routine cases per application before going live.¹⁷ A large-scale validation in Wales scanning over 7,400 slides from 3,000 cases found good diagnostic concordance between digital and glass-slide reads.¹⁸

Once slides are digitized, artificial intelligence enters the picture. Machine learning algorithms trained on annotated datasets can assist with tumor detection, grading, and automated quantification of biomarker expression on whole-slide images.¹⁹ AI tools are being developed to interpret H&E stains for tumor classification, grading, and biomarker quantification, with clinical applications already emerging for targets like HER2 and PD-L1.²⁰ The technology is promising but not yet plug-and-play. Challenges in model interpretability, real-world validation, and integration with existing clinical workflows remain significant hurdles.²¹

The Pathology Report

Everything in the workflow converges in the pathology report, the document that clinicians and patients actually see. For cancer cases, the report typically includes the tumor type, grade, stage, margin status, and results of any ancillary testing. How this information is communicated matters. Traditionally, pathologists dictated narrative-style reports, a free-text approach that allows flexibility but risks omitting key data elements. Synoptic reporting, which uses structured templates with standardized fields, has been shown to dramatically improve completeness. One study found that template-based synoptic reports captured about 98% of mandatory data elements, compared to 77% for narrative reports.²² A systematic review across multiple cancer types confirmed this pattern, with 13 of 14 studies showing increased overall completeness when synoptic formats were adopted.²³

Behind the scenes, the report’s journey from pathologist to clinician is managed by laboratory information systems (LIS). These systems register specimens, track them through every stage of the workflow, and ultimately disseminate finalized reports across the health system.²⁴ As molecular testing has expanded, some labs have adopted dedicated laboratory information management systems (LIMS) layered on top of the standard LIS to handle the complex data packets and automation that genomic workflows demand.²⁵

Liquid Biopsy as a Complement to Tissue

The entire workflow described above assumes you have a tissue specimen. But a growing body of evidence supports the use of liquid biopsies, blood draws that capture cell-free DNA (cfDNA) shed by tumors into the bloodstream, as a complement to traditional pathology. In gastrointestinal cancers with acquired drug resistance, a prospective study found that cfDNA detected resistance alterations missed by matched tissue biopsy in 78% of cases, largely because tumors develop multiple resistance mechanisms in different locations that a single biopsy cannot capture.²⁶

This does not mean liquid biopsy is ready to replace tissue-based pathology. In lung adenocarcinoma, direct comparison showed tissue sequencing had a sensitivity of about 95% for clinically relevant mutations, while plasma sequencing detected only about 53%.²⁷ In colorectal cancer, the concordance was better, with cfDNA even revealing additional variants in some patients.²⁸ The emerging consensus is that liquid biopsy is most valuable for monitoring treatment resistance and tracking tumor evolution over time, while tissue biopsy remains the more sensitive tool for initial diagnosis and comprehensive mutation profiling. The two approaches are increasingly used together rather than as competitors.

Chemical Hazards in the Pathology Lab

Something that rarely comes up in clinical discussions but matters to the tens of thousands of people who work in pathology labs: the chemicals that make this workflow possible are hazardous. Formaldehyde, the active ingredient in formalin, is a known carcinogen and respiratory irritant. Xylene, used in the clearing step of tissue processing, is a volatile organic solvent that causes headaches, dizziness, and with chronic exposure, potential neurological effects.²⁹ Laboratory personnel who handle these chemicals daily face occupational exposure risks that require ventilated workstations, personal protective equipment, and regular health surveillance.³⁰ Research into natural and less toxic alternatives for histology reagents is ongoing, though formalin and xylene remain deeply entrenched in practice because of their reliability and the enormous body of established protocols built around them.

How Staining Has Evolved and Where It Is Heading

The staining techniques that underpin modern pathology have their roots in the nineteenth century. Early histological stains like carmine, silver nitrate, and hematoxylin were discovered in nature and adopted for medical use as microscopy became a clinical tool. Hematoxylin and eosin, Ziehl-Neelsen stain for tuberculosis, Periodic Acid–Schiff, and Grocott-Gomori methenamine silver are among the stains that emerged as the field matured and remain in wide use today.³¹ What has changed dramatically is the addition of immunohistochemical and immunofluorescent techniques that go beyond staining tissue components by their chemical properties. These methods label specific gene products and proteins, allowing pathologists to characterize individual cells at a molecular level without destroying the nuclear material that older chemical stains sometimes damaged. As genomic and proteomic technologies continue to advance, the trend is toward multiplexed staining, where multiple targets are labeled simultaneously on a single slide, giving pathologists an increasingly detailed molecular portrait of disease.